NorthCrest Asset Manangement LLC raised its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 0.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,534 shares of the company’s stock after buying an additional 381 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Novartis were worth $6,618,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Founders Financial Securities LLC lifted its stake in shares of Novartis by 3.4% in the 2nd quarter. Founders Financial Securities LLC now owns 2,832 shares of the company’s stock valued at $301,000 after purchasing an additional 94 shares during the period. Steigerwald Gordon & Koch Inc. lifted its position in Novartis by 4.8% during the third quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock valued at $241,000 after buying an additional 95 shares during the period. NBC Securities Inc. boosted its holdings in shares of Novartis by 0.9% during the 2nd quarter. NBC Securities Inc. now owns 10,492 shares of the company’s stock valued at $1,116,000 after buying an additional 97 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Novartis by 5.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,013 shares of the company’s stock worth $196,000 after buying an additional 98 shares during the period. Finally, Portside Wealth Group LLC increased its stake in shares of Novartis by 3.4% in the 2nd quarter. Portside Wealth Group LLC now owns 3,000 shares of the company’s stock worth $319,000 after acquiring an additional 99 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.
Novartis Stock Performance
Shares of NYSE NVS opened at $113.79 on Friday. The firm’s 50-day moving average price is $116.42 and its 200-day moving average price is $108.55. Novartis AG has a 52-week low of $92.19 and a 52-week high of $120.92. The company has a market cap of $232.59 billion, a PE ratio of 15.36, a PEG ratio of 1.66 and a beta of 0.57. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47.
Analysts Set New Price Targets
Read Our Latest Stock Report on NVS
Novartis Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Further Reading
- Five stocks we like better than Novartis
- Golden Cross Stocks: Pattern, Examples and Charts
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Calculate Return on Investment (ROI)
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Energy and Oil Stocks Explained
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.